In case of recurrence with metastases, the prognosis of this cancer has not improved over the past twenty years, due to a lack of effective therapies..
Article written by
Published
Update
Reading time : 1 min.
Collective Pink triplets calls for urgent access to innovative treatments for patients with extremely aggressive triple-negative breast cancer. Little known, this cancer which affects about 15% of patients with breast cancer, or 9,000 new cases per year, mainly concerns young women. The risk of recurrence is high: 30% within three years of diagnosis.
In the event of recurrence with metastases, the prognosis of this cancer has not improved over the past twenty years, for lack of effective therapies. The five-year survival rate is 11.3%. Its characteristic: it does not present any marker (hormone receptors or HER2 protein) on the surface of cancerous cells, likely to respond to an existing targeted therapy.
A year ago, the collective #MobilisationTriplettes was created, which in December became the association Triplettes roses. Three days before World Triple Negative Breast Cancer Day, this collective calls for “urgently” access to innovative treatments, citing the examples of vaccine therapy, immunotherapy, or conjugated antibodies.
Thanks in particular to its action, the French health authorities approved the use of two treatments last fall, Keytruda and Trodelvy. The group would also like “a project to set up a national platform for clinical trials” for women with this cancer.